A detailed history of California State Teachers Retirement System transactions in Nuvation Bio Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 135,389 shares of NUVB stock, worth $299,209. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135,389
Previous 14,646 824.41%
Holding current value
$299,209
Previous $53,000 645.28%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.58 - $3.69 $311,516 - $445,541
120,743 Added 824.41%
135,389 $395,000
Q1 2024

May 15, 2024

SELL
$1.46 - $3.97 $13,624 - $37,048
-9,332 Reduced 38.92%
14,646 $53,000
Q4 2023

Feb 13, 2024

SELL
$0.96 - $1.53 $110,029 - $175,359
-114,614 Reduced 82.7%
23,978 $36,000
Q3 2023

Nov 14, 2023

SELL
$1.26 - $2.1 $19,202 - $32,004
-15,240 Reduced 9.91%
138,592 $185,000
Q2 2023

Aug 21, 2023

BUY
$1.56 - $1.84 $8,611 - $10,156
5,520 Added 3.72%
153,832 $276,000
Q1 2023

May 09, 2023

SELL
$1.6 - $2.48 $2,990 - $4,635
-1,869 Reduced 1.24%
148,312 $246,000
Q4 2022

Feb 14, 2023

BUY
$1.68 - $2.5 $2,493 - $3,710
1,484 Added 1.0%
150,181 $288,000
Q3 2022

Nov 18, 2022

SELL
$0.29 - $4.04 $882 - $12,297
-3,044 Reduced 2.01%
148,697 $333,000
Q2 2022

Aug 15, 2022

SELL
$3.24 - $5.85 $31,440 - $56,768
-9,704 Reduced 6.01%
151,741 $492,000
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $79,529 - $152,661
-17,289 Reduced 9.67%
161,445 $849,000
Q4 2021

Feb 15, 2022

BUY
$7.75 - $10.05 $347,091 - $450,099
44,786 Added 33.44%
178,734 $1.52 Million
Q3 2021

Nov 15, 2021

BUY
$7.78 - $10.0 $661,611 - $850,400
85,040 Added 173.88%
133,948 $1.33 Million
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $450,931 - $708,187
48,908 New
48,908 $455,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $480M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.